It's another win for gene-targeted cancer drugs in lung cancer. The new data sets up a duel between Loxo and another biotechnology firm, Blueprint Medicines, which showed off data from a similar targeted drug in April.
from Forbes Real Time https://www.forbes.com/sites/matthewherper/2018/06/02/loxo-scores-another-success-but-fda-path-could-be-complicated/
via IFTTT
No comments:
Post a Comment